Literature DB >> 2690320

Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH.

M Wienbeck1, Q Li.   

Abstract

Since gastro-oesophageal reflux disease is due to disturbances of oesophageal motility, motor and pH measurements are an important means to test a new anti-reflux drug, cisapride. In oesophageal manometry cisapride increased the pressure of the lower oesophageal sphincter in healthy volunteers and patients, and in the majority of studies it also strengthened the amplitude of oesophageal contractions. Cisapride lowered the total duration of acid exposure in the lower oesophagus in both volunteers and reflux patients. Thus cisapride may be useful in the treatment of gastro-oesophageal reflux disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690320     DOI: 10.3109/00365528909091226

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures.

Authors:  J R Malagelada; E Distrutti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

2.  Preservation of the lower esophageal sphincter during total gastrectomy for gastric cancer to prevent postoperative reflux esophagitis.

Authors:  T Hirai; S Saeki; K Matsuki; Y Yamashita; T Iwata; A Yoshimoto; T Toge
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 3.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Prevention of aspiration pneumonia during long-term feeding by percutaneous endoscopic gastrostomy: might cisapride play any role? An open pilot study.

Authors:  S Sartori; L Trevisani; D Tassinari; I Nielsen; G Gilli; D Donati; P Malacarne
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

5.  Metoclopramide inhibits development of esophageal varices in rat model.

Authors:  M Ohta; M Hashizume; K Tanoue; K Ueno; K Komori; T Ishii; S Kitano; K Sugimachi
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

Review 6.  A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders.

Authors:  J Tack; G Coremans; J Janssens
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

Review 7.  Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

8.  Cisapride enhances the effect of partial posterior fundoplication on esophageal peristalsis in GERD patients with poor esophageal contractility.

Authors:  G J Wetscher; K Glaser; T Wieschemeyer; M Gadenstätter; P Klingler; A Klingler; R A Hinder
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.